Inclusivity in prostate cancer and exercise research: a systematic review

Support Care Cancer. 2024 Aug 28;32(9):616. doi: 10.1007/s00520-024-08793-9.

Abstract

Background: Prostate cancer (PCa) is the most prevalent type of cancer in men in the UK. Exercise has been shown to improve the health and quality of life of PCa patients. Exercise should be easily accessible to men with PCa regardless of socioeconomic group or ethnicity. There is a need to better understand whether the current evidence base for exercise interventions is representative and inclusive of racial and ethnic minority men with PCa.

Methods: A systematic review of the literature was conducted according to PRISMA guidelines and prospectively registered via Prospero (ID: CRD42022384373). The MEDLINE Ovid, Cochrane Library and PubMed databases were searched from inception to December 2022. The search strategy keywords and MeSH terms used included the following: (1) exercise, (2) training, (3) prostate cancer, (4) ethnic and (5) diversity.

Results: A total of 778 records were retrieved from database searches, of which 15 records were duplicates. A further 649 were eliminated following the screening of titles and abstracts. After full-text screening of 186 articles, 28 manuscripts were included for review.

Conclusion: This systematic review highlights that there is high heterogeneity in the reporting of participants' ethnicity and there are low numbers of ethnic minority men included in PCa and exercise studies in the UK. Further work is required to understand why representation is lacking within PCa exercise trials in the UK and strategies are needed to achieve representation from all ethnic groups.

Implications for cancer survivors: Improved representation and reporting of ethnicity in exercise trials is vital to ensure the results are applicable to all patients.

Keywords: Ethnic diversity; Exercise; Inclusivity; Prostate cancer.

Publication types

  • Systematic Review
  • Review

MeSH terms

  • Ethnicity
  • Exercise
  • Exercise Therapy / methods
  • Humans
  • Male
  • Prostatic Neoplasms* / therapy
  • Quality of Life*
  • United Kingdom